Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.


TSX:CPH - Post by User

Comment by lorbason Nov 18, 2020 1:53pm
138 Views
Post# 31923534

RE:RE:RE:RE:RE:Strong Cash Position at exit 2020

RE:RE:RE:RE:RE:Strong Cash Position at exit 2020"As much as business is business, Mull's personality and perceived intent are both strong deterrents to resuming discussion."

Lol. Of course Bausch doesn't like Mull. They want to market Trulance for themselves, and Mull is defending the company's rights to this valuable asset. He would do something wrong, if Bausch liked him at his point. I expect him to be a pain in the a$$ for those bullies and squeeze every penny from them possible. 

I hope the arbitrator will see the game Bausch plays for what it is and impose a hefty penalty on those bozos.  
<< Previous
Bullboard Posts
Next >>